ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

By |2021-02-12T15:51:13+00:0012 Feb 2021|Drug treatments|

In a small phase 2 study presented at the virtual [...]